Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499 on ClinicalTrials.gov · last registry update 2026-03-27

Recruiting now, toward 63 participants. Due to report 31 December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change in number of kilograms of lean mass by dual-energy x-ray absorptiometry. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Massachusetts General Hospital
Sponsor type: Other
Enrollment: 63
Started: 2025-11-05
Primary completion: 2028-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in number of kilograms of lean mass by dual-energy x-ray absorptiometry

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.